Clincosm LogoSign in Get a demo

marginal zone lymphoma

Showing 1 - 25 of 103
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

B-cell Malignancies Undergoing Treatment With Bruton Tyrosine

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +4 more
  • Non-Interventional Study
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Nov 22, 2023

Marginal Zone Lymphoma Trial ([68Ga]Ga-PentixaFor, [18F]Fluorodeoxyglucose)

Not yet recruiting
  • Marginal Zone Lymphoma
  • (no location specified)
Nov 6, 2023

Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,

Not yet recruiting
  • Non-hodgkin Lymphoma
  • +9 more
  • CD79b-19 CAR T cells
  • +2 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Sep 6, 2023

Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma Trial in United States (P-CD19CD20-ALLO1, Rimiducid)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • +5 more
  • La Jolla, California
  • +7 more
Aug 25, 2023

Marginal Zone Lymphoma Trial (Mosunetuzumab + Lenalidomide, - Rituximab + Lenalidomide (28-days cycles, - Rituximab +

Not yet recruiting
  • Marginal Zone Lymphoma
  • Mosunetuzumab + Lenalidomide
  • +3 more
  • (no location specified)
Aug 16, 2023

Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (Pirtobrutinib, LV20.19 CAR T cells)

Not yet recruiting
  • Non Hodgkin Lymphoma
  • +5 more
  • (no location specified)
Aug 4, 2023

Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma Trial (FT596, Cyclophosphamide,

Withdrawn
  • Diffuse Large B Cell Lymphoma
  • +4 more
  • (no location specified)
Jun 28, 2023

(CHANT)Real World Study of Duvelisib in Treatment of

Not yet recruiting
  • Follicular Lymphoma
  • +5 more
  • (no location specified)
Jun 20, 2023

Extranodal Lymphoma or Lymphoma of Rare Pathological Types

Not yet recruiting
  • Lymphoma
  • +8 more
  • No interventions need to be specified for this study
  • Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
Jun 15, 2023

Marginal Zone Lymphoma Trial in Tianjin (Obinutuzumab, lenalidomide)

Recruiting
  • Marginal Zone Lymphoma
  • Obinutuzumab, lenalidomide
  • Tianjin, Tian, China
    Institute of Hematology & Blood Diseases Hospital
Apr 27, 2023

Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial (BGB-21447)

Not yet recruiting
  • Relapsed Non-Hodgkin Lymphoma
  • +6 more
  • (no location specified)
Apr 12, 2023

Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Biphenotypic Acute Leukemia Trial in Minneapolis (biological, drug,

Not yet recruiting
  • Acute Myelogenous Leukemia
  • +17 more
  • Peripheral Blood Stem Cell Transplant
  • +7 more
  • Minneapolis, Minnesota
    Masonic Cancer Center at University of Minnesota
Mar 27, 2023

Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma Trial in Boston (Obinutuzumab, Glofitamab)

Not yet recruiting
  • Follicular Lymphoma
  • +2 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Mar 13, 2023

B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL Trial in Louisville (Cyclophosphamide, Fludarabine, ACE1831)

Recruiting
  • B-cell Lymphoma
  • +5 more
  • Louisville, Kentucky
    Norton Cancer Institute
Jan 24, 2023

Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)

Recruiting
  • Follicular Lymphoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

CLL, SLL, Richter's Transformation Trial in United States (TG-1801, Ublituximab)

Recruiting
  • CLL
  • +9 more
  • TG-1801
  • Ublituximab
  • Fayetteville, Arkansas
  • +4 more
Jan 20, 2023

Marginal Zone Lymphoma and Its Prognostic Role

Recruiting
  • Marginal Zone Lymphoma
    • Dijon, France
    • +22 more
    Jan 17, 2023

    B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma Trial in Australia, United States (BGB-16673)

    Recruiting
    • B-cell Malignancy
    • +8 more
    • Phoenix, Arizona
    • +14 more
    Jan 17, 2023

    Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma Trial in United States (Zilovertamab vedotin)

    Active, not recruiting
    • Chronic Lymphocytic Leukemia
    • +11 more
    • Zilovertamab vedotin
    • Duarte, California
    • +13 more
    Jan 12, 2023

    Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Marginal Zone Lymphoma Trial in France (Atezolizumab, Obinutuzumab,

    Completed
    • Follicular Lymphoma
    • +3 more
    • Angers, France
    • +24 more
    Jan 9, 2023

    Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Follicular Lymphoma Trial in Australia, China (BGB-10188,

    Recruiting
    • Chronic Lymphocytic Leukemia
    • +9 more
    • Adelaide, Australia
    • +12 more
    Jan 6, 2023

    Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia Trial in Worldwide (Iopofosine I 131 single dose,

    Recruiting
    • Waldenstrom Macroglobulinemia
    • +8 more
    • Iopofosine I 131 single dose
    • +2 more
    • Redlands, California
    • +42 more
    Dec 30, 2022

    Follicular Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone Lymphoma Trial in Seattle (Laboratory Biomarker

    Active, not recruiting
    Has Results
    • Follicular Lymphoma
    • +2 more
    • Laboratory Biomarker Analysis
    • Pembrolizumab
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Dec 6, 2022

    Non-Hodgkin Lymphoma, Follicular Lymphoma, DLBCL Trial in Australia, Korea, Republic of, United States (IGM-2323)

    Recruiting
    • Non-Hodgkin Lymphoma
    • +4 more
    • Duarte, California
    • +23 more
    Dec 28, 2022

    Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Trial in Aurora, Seattle (drug, procedure,

    Active, not recruiting
    • Acute Biphenotypic Leukemia
    • +18 more
    • Aurora, Colorado
    • +2 more
    Dec 28, 2022